Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02677922
Registration number
NCT02677922
Ethics application status
Date submitted
5/02/2016
Date registered
9/02/2016
Date last updated
25/01/2024
Titles & IDs
Public title
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Query!
Scientific title
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Query!
Secondary ID [1]
0
0
2015-003951-23
Query!
Secondary ID [2]
0
0
AG-221-AML-005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Leukemia, Myeloid, Acute
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AG-120
Treatment: Drugs - Azacitidine
Treatment: Drugs - AG-221
Experimental: AG-120 + Azacitidine -
Experimental: AG-221 + Azacitidine -
Experimental: Azacitidine -
Treatment: Drugs: AG-120
Specified dose on specified days
Treatment: Drugs: Azacitidine
Specified dose on specified days
Treatment: Drugs: AG-221
Specified dose on specified days
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)
Query!
Assessment method [1]
0
0
Dose-limiting toxicities (DLTs) are defined as an event that constitute a change from baseline irrespective of outcome and determined by the investigator to be related to treatment. The DLT-evaluable participants were defined as participants who took at least 1 dose of study drug in the Phase 1b Dose-Finding Stage and either had a DLT during Cycle 1 (regardless of amount of study drug exposure), or had no DLT and completed at least 75% of AG-120 or AG-221 doses (21 out of 28 days) and a minimum of 5 doses of AZA, at least 50% of the planned combination doses for AG-120 or AG-221 and AZA administered together (in the same day for 4 out of 7 days) in the first 28 days from C1D1, and were also considered by the Clinical Study Team to have sufficient safety data available to conclude that a DLT did not occur during Cycle 1.
Query!
Timepoint [1]
0
0
From first dose to 28 days after first dose
Query!
Primary outcome [2]
0
0
The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)
Query!
Assessment method [2]
0
0
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
Query!
Timepoint [2]
0
0
From first dose to 28 days after last dose (up to approximately 13 months)
Query!
Primary outcome [3]
0
0
Overall Response Rate: Phase 2 (Randomized Stage)
Query!
Assessment method [3]
0
0
The percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of =200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) =1,000/µL, Platelet count =100,000/µL, and independent of red cell transfusions for =1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Query!
Timepoint [3]
0
0
From first dose up to approximately 26 months
Query!
Secondary outcome [1]
0
0
Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage)
Query!
Assessment method [1]
0
0
Percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of =200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) =1,000/µL, Platelet count =100,000/µL, and independent of red cell transfusions for =1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Query!
Timepoint [1]
0
0
From first dose up to approximately 13 months
Query!
Secondary outcome [2]
0
0
Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)
Query!
Assessment method [2]
0
0
The percent of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC = 1 x 109/L (1,000/µL), platelet count = 100 x 109/L (100,000/µL), independent of red cell transfusions for = 1 week immediately before each response assessment. CRh is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/µL) \& Platelet count \> 50 x 109/L (100,000/µL). CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.
Query!
Timepoint [2]
0
0
From first dose up to approximately 13 months
Query!
Secondary outcome [3]
0
0
Event-free Survival (EFS): Phase 2 (Randomized Stage)
Query!
Assessment method [3]
0
0
Event-Free Survival is the time from date of randomization to the date of documented morphologic relapse, progression, or death from any cause, whichever occurs first. Morphologic Relapse is defined as either reappearance of = 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression is defined as a \> 50% increase of BM blast count percentage from baseline to = 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to = 10 x 109/L (10,000/µL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.
Query!
Timepoint [3]
0
0
From randomization to the date of documented relapse, progression, or death due to any cause, whichever occurs first (up to approximately 26 months)
Query!
Secondary outcome [4]
0
0
The Number of Participants Experiencing Adverse Events: Phase 2 (Randomized Stage)
Query!
Assessment method [4]
0
0
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
Query!
Timepoint [4]
0
0
From first dose to 28 days after last dose (up to approximately 26 months)
Query!
Secondary outcome [5]
0
0
Complete Remission Rate: Phase 2 (Randomized Stage)
Query!
Assessment method [5]
0
0
The percent of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) =1,000/µL, Platelet count =100,000/µL, and independent of red cell transfusions for =1 week before each response assessment.
Query!
Timepoint [5]
0
0
From first dose up to approximately 26 months
Query!
Secondary outcome [6]
0
0
Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)
Query!
Assessment method [6]
0
0
The percent of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by = 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of = 30 X 10\^9/L for participants starting with \> 20 X and an increase from \< 20 X 10\^9/L to \> 20 X 10\^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase \> 0.5 X 10\^9/L.
Query!
Timepoint [6]
0
0
From first dose up to approximately 26 months
Query!
Secondary outcome [7]
0
0
Duration of Response: Phase 2 (Randomized Stage)
Query!
Assessment method [7]
0
0
The time from first documented CR/CRi/CRp/PR/MLFS to documented morphologic relapse, progression, or death due to any cause, whichever occurred first. CR and MLFS are defined as \<5% blasts in a BM aspirate sample with marrow spicules + a count of =200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC = 1,000/µL, Platelet count =100,000/µL, + independent of red cell transfusions for =1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with \>50% decrease in BM blasts to 5%-25%. Relapse is defined as reappearance of = 5% blasts in the BM not attributable to other cause or development of extramedullary disease. Progression is defined as \> 50% increase of BM blast count from baseline to = 20% or a doubling of absolute blast count in peripheral blood from baseline to = 10,000/µL or development of new extramedullary disease.
Query!
Timepoint [7]
0
0
From first dose up to approximately 26 months
Query!
Secondary outcome [8]
0
0
Time to Response: Phase 2 (Randomized Stage)
Query!
Assessment method [8]
0
0
Time from first dose of study drug to first documented MLFS/CR/CRi/CRp/PR according to modified IWG AML response criteria. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of =200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) =1,000/µL, Platelet count =100,000/µL, and independent of red cell transfusions for =1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Query!
Timepoint [8]
0
0
From first dose to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 26 months)
Query!
Secondary outcome [9]
0
0
Overall Survival: Phase 2 (Randomized Stage)
Query!
Assessment method [9]
0
0
Overall survival (OS) is defined as time from randomization to death due to any cause.
Query!
Timepoint [9]
0
0
From randomization to date of death (up to approximately 26 months)
Query!
Secondary outcome [10]
0
0
One Year Survival Rate: Phase 2 (Randomized Stage)
Query!
Assessment method [10]
0
0
The percent of participants alive at 1 year from randomization
Query!
Timepoint [10]
0
0
From randomization to 1 year after randomization
Query!
Secondary outcome [11]
0
0
AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 1B (Expansion Stage)
Query!
Assessment method [11]
0
0
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.
Query!
Timepoint [11]
0
0
Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Query!
Secondary outcome [12]
0
0
Cmax- Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
Query!
Assessment method [12]
0
0
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data
Query!
Timepoint [12]
0
0
Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Query!
Secondary outcome [13]
0
0
Tmax- Time of Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
Query!
Assessment method [13]
0
0
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Query!
Timepoint [13]
0
0
Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Query!
Secondary outcome [14]
0
0
AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
Query!
Assessment method [14]
0
0
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.
Query!
Timepoint [14]
0
0
Pre-dose, 2, 3, 4, 6, and 8 hours post dose (± 10 minutes) on day 1 of cycle 2
Query!
Secondary outcome [15]
0
0
AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
Query!
Assessment method [15]
0
0
AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours, calculated using the linear trapezoid rule.
Query!
Timepoint [15]
0
0
Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Query!
Secondary outcome [16]
0
0
Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
Query!
Assessment method [16]
0
0
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Query!
Timepoint [16]
0
0
Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Query!
Secondary outcome [17]
0
0
Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
Query!
Assessment method [17]
0
0
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Query!
Timepoint [17]
0
0
Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Query!
Secondary outcome [18]
0
0
Change From Baseline in Health-related Quality-of-Life Domain Scores of the EORTC QLQ-C30: Phase 2 (Randomized Stage)
Query!
Assessment method [18]
0
0
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. EORTC QLQ-C30 is assessed prior to dosing and prior to interaction with study personnel.
Query!
Timepoint [18]
0
0
Baseline and Day 1 Cycle 5
Query!
Secondary outcome [19]
0
0
Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)
Query!
Assessment method [19]
0
0
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
Query!
Timepoint [19]
0
0
Baseline and Day 1 Cycle 5
Query!
Secondary outcome [20]
0
0
Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)
Query!
Assessment method [20]
0
0
The European Quality of Life 5D-5L (EQ-5D-5L) instrument has a respondent's self-rated today's health scale which is recorded on a VAS with endpoints labeled "the best health you can imagine" and "the worst health you can imagine." The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of QoL. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
Query!
Timepoint [20]
0
0
Baseline and Day 1 Cycle 5
Query!
Secondary outcome [21]
0
0
Sponsor Derived CR: Phase 2 (Randomized Stage)
Query!
Assessment method [21]
0
0
The number of participants with Morphologic Complete Remission (CR) based on laboratory data. CR is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC = 1 x 109/L (1,000/µL), platelet count = 100 x 109/L (100,000/µL), independent of red cell transfusions for = 1 week immediately before each response assessment.
Query!
Timepoint [21]
0
0
From first dose to end of study
Query!
Secondary outcome [22]
0
0
Sponsor Derived CR and CRh: Phase 2 (Randomized Phase)
Query!
Assessment method [22]
0
0
The number of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC = 1 x 109/L (1,000/µL), platelet count = 100 x 109/L (100,000/µL), independent of red cell transfusions for = 1 week immediately before each response assessment. CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.
Query!
Timepoint [22]
0
0
From first dose to end of study
Query!
Secondary outcome [23]
0
0
Time to Sponsor Derived CR and CRh: Phase 2 (Randomized Phase)
Query!
Assessment method [23]
0
0
Time from first dose of study drug to first documented CR/CRh. Morphologic Complete Remission (CR) is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC = 1 x 109/L (1,000/µL), platelet count = 100 x 109/L (100,000/µL), independent of red cell transfusions for = 1 week immediately before each response assessment. Morphologic complete remission with partial hematologic recovery (CRh) is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/µL) \& Platelet count \> 50 x 109/L (100,000/µL).
Query!
Timepoint [23]
0
0
From first dose to end of study
Query!
Secondary outcome [24]
0
0
Duration of Sponsor Derived CR/CRh: Phase 2 (Randomized Stage)
Query!
Assessment method [24]
0
0
Time from first documented CR/CRh to documented morphologic relapse, PD, or death due to any cause, whichever occurred first. Participants without morphologic relapse, PD, or death due to any cause were censored at the date of the last response assessment. Morphologic Relapse is defined as either reappearance of = 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression (PD) is defined as a \> 50% increase of BM blast count percentage from baseline to = 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to = 10 x 109/L (10,000/µL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.
Query!
Timepoint [24]
0
0
From first dose to end of study
Query!
Eligibility
Key inclusion criteria
* Newly diagnosed, primary (ie, de novo) or secondary (progression of Myelodysplastic syndrome [MDS] or myeloproliferative neoplasms [MPN], or therapy-related) acute myeloid leukemia (AML) according to the WHO classification with = 20% leukemic blasts in the bone marrow
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* Agree to serial bone marrow aspirate/biopsies
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype
* AML secondary to chronic myelogenous leukemia (CML)
* Received a targeted agent against an isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutation
* Has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening
Other protocol defined inclusion/exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/06/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/10/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
130
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
Local Institution - 178 - Adelaide
Query!
Recruitment hospital [2]
0
0
Local Institution - 175 - Melbourne
Query!
Recruitment hospital [3]
0
0
Local Institution - 177 - Perth
Query!
Recruitment postcode(s) [1]
0
0
SA 5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3141 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Yvoir
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Ontario
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Lille
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Marseille Cedex 9
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Paris Cedex 10
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Pessac
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Pierre Benite
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Toulouse
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Villejuif CEDEX
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Berlin
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Dresden
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Ulm
Query!
Country [19]
0
0
Italy
Query!
State/province [19]
0
0
Bologna, Emilia-Romagna
Query!
Country [20]
0
0
Italy
Query!
State/province [20]
0
0
Firenze
Query!
Country [21]
0
0
Italy
Query!
State/province [21]
0
0
Genova
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Orbassano
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Padova
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
Pesaro
Query!
Country [25]
0
0
Italy
Query!
State/province [25]
0
0
Roma
Query!
Country [26]
0
0
Korea, Republic of
Query!
State/province [26]
0
0
Seoul
Query!
Country [27]
0
0
Netherlands
Query!
State/province [27]
0
0
Utrecht
Query!
Country [28]
0
0
Portugal
Query!
State/province [28]
0
0
Lisboa
Query!
Country [29]
0
0
Spain
Query!
State/province [29]
0
0
Barcelona
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Caceres
Query!
Country [31]
0
0
Spain
Query!
State/province [31]
0
0
Madrid
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Malaga
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Valencia
Query!
Country [34]
0
0
Sweden
Query!
State/province [34]
0
0
Göteborg
Query!
Country [35]
0
0
Switzerland
Query!
State/province [35]
0
0
Basel
Query!
Country [36]
0
0
Switzerland
Query!
State/province [36]
0
0
Zurich
Query!
Country [37]
0
0
United Kingdom
Query!
State/province [37]
0
0
Birmingham
Query!
Country [38]
0
0
United Kingdom
Query!
State/province [38]
0
0
Headington
Query!
Country [39]
0
0
United Kingdom
Query!
State/province [39]
0
0
London
Query!
Country [40]
0
0
United Kingdom
Query!
State/province [40]
0
0
Sutton (Surrey)
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Celgene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02677922
Query!
Trial related presentations / publications
DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Dohner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 Nov;22(11):1597-1608. doi: 10.1016/S1470-2045(21)00494-0. Epub 2021 Oct 18. DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Dohner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29. Erratum In: J Clin Oncol. 2021 Feb 1;39(4):341. doi: 10.1200/JCO.20.03658.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/22/NCT02677922/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/22/NCT02677922/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02677922
Download to PDF